News for CVRx, Inc. (CVRX)

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx (NASDAQ: CVRX) will release its Q2 2025 earnings on August 4, 2025, after market close. A conference call to discuss the results is scheduled for 4

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ( CVRX) (”œCVRx”), a commercial-stage medical device company, announced today that the Centers fo

CVRx (CVRX) will see a maintained reimbursement rate for Barostim implant procedures at approximately $45,000. Barostim transitions to a higher-paying M

CVRx (CVRX) has received a proposal from the Centers for Medicare and Medicaid Services (CMS) to maintain the Barostim implant procedure within the New Technolo

CVRx's FDA-approved heart failure therapy, strong growth potential, and discounted valuation make it a compelling speculative Buy opportunity. See more on CVRX stock.

**media[639765]**

On May 12, 2025, Kevin Hykes, President and Chief Executive Officer of CVRx Inc, purchased 5,000 shares of the company, as reported in the SEC Filing. This tran

CVRx, Inc. (NASDAQ:CVRX) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsKevin Hykes - President & CEOJared Oasheim - CFOMike...

CVRx (CVRX) stock falls as the company's Q1 2025 results fall short of growth targets, leading to a downgrade at J.P. Morgan. Read more here.

On May 9, 2025, Piper Sandler maintained their "Overweight" rating for CVRx (CVRX) but lowered their price target significantly. The new price target is set at

Piper Sandler analyst Matt O'Brien has adjusted the price target for CVRx (CVRX) shares from $20 to $12, while maintaining an Overweight rating. This decision f

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

JPMorgan has lowered its rating on CVRx (CVRX) from Neutral to Underweight and adjusted its price target from $15 to $7. The downgrade comes after the company f

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NCVRX.OQ - CVRx IncQ1 2025 CVRx Inc Earnings CallMay 08, 2025 / 08:30PM GMT ===================